• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics COVID-19 Classics

The EMPACTA trial: Tocilizumab reduced COVID-19 disease-related adverse health outcomes [Classics Series]

byDeepti Shroff Karhade
July 15, 2022
in COVID-19 Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2. Treatment with tocilizumab did not improve survival among patients.

Original Date of Publication: December 2020

Study Rundown: Cases pertaining to the coronavirus disease 2019 (COVID-19) have led to severe clinical manifestations requiring mechanical ventilation. However, fatal outcomes have still resulted despite currently treatments and supportive care. This trial investigated the safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in patients hospitalized with COVID-19 pneumonia. These hospitalized patients were randomly assigned into one of two groups after informed consent was obtained. Patients were followed for two months and outcomes such as the need for mechanical ventilation or death were assessed on day 28. The trial results displayed both the efficacy and safety of tocilizumab treatment in managing patients with COVID-19 pneumonia. However, both groups revealed similar death outcomes. The study was strengthened by its focus on the inclusion of ethnic and racial minority patients. Conversely, the study was limited by the short follow-up period. Nonetheless, the study results are important as they showed tocilizumab reduces adverse health outcomes related to COVID-19.

Click to read the study in NEJM

In-Depth [randomized control trial]: This phase 3, double-blind trial enrolled 389 participants across multiple countries including Brazil, Kenya, Mexico, Peru, South Africa, and the United States. This study enrolled patients over the age of 18 with confirmed COVID-19 pneumonia who were hospitalized. Patients were excluded if they required additional breathing assistance such as continuous positive airway pressure, mechanical ventilation, or bilevel positive airway pressure. Patients were randomized in a 2:1 ratio to the standard of care including one or two doses of either tocilizumab or a placebo, respectively. On day 28, the primary endpoint of mechanical ventilation or death was evaluated for all participants. The results were further investigated using analysis and stratification, where the median follow-up time was 60 days.

RELATED REPORTS

Unvaccinated status increases risk of long COVID symptoms

The 2 Minute Medicine Podcast Episode 6

Perfluorohexyloctane drops significantly improve dry eye due to Meibomian gland dysfunction

By day 28, an overall of 12% (95%CI 8.5-16.9%) of the patients in the tocilizumab group had either received some form of mechanical ventilation or had died, whereas a total of 19.3% (95% CI 13.3-27.4%) of the placebo group had experienced these outcomes. The hazard ratio for mechanical ventilation or death between both groups was 0.56 (95%CI 0.33-0.97 p = 0.04). Furthermore, 15.2% of the patients reported serious adverse events in the study drug group compared to 19.7% were reported in the placebo. Consequently, more deaths were reported in the placebo group (29 patients) compared to the tocilizumab group (15 patients), although all-cause mortality at 28 days did not differ significantly between the two groups (weight difference 2.0; 95%CI −5.2 to 7.8). Overall, these findings demonstrate that tocilizumab is both safe and effective in treating patients with COVID-19 pneumonia.

Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia. N Engl J Med. 2021 Jan 7;384(1):20–30.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #COVID-19 pneumoniaCoronavirusphase 3 trialSARS-CoV-2Tocilizumab
Previous Post

The COVE trial: mRNA-1273 vaccine for preventing COVID-19 [Classics Series]

Next Post

10-second one-legged stance performance may predict survival in middle-aged and older individuals

RelatedReports

Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
Adalimumab aids in control of noninfectious uveitis
Ophthalmology

Perfluorohexyloctane drops significantly improve dry eye due to Meibomian gland dysfunction

January 9, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: the Future of Medicine, Neuralink, the Spotlight on Celine Dion and COVID-19 on Social Media

December 27, 2022
Next Post
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

10-second one-legged stance performance may predict survival in middle-aged and older individuals

#VisualAbstract: Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery

#VisualAbstract: Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery

Racial and ethnic disparities in trends and outcomes of cardiogenic shock and peripartum cardiomyopathy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
  • Homicide deaths are on the rise for children living in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options